Legend Star
Legend Star closes fifth renminbi fund on $123m
Legend Star, the China-based venture capital arm of Legend Holdings, has closed its fifth renminbi-denominated fund with more than CNY 900m (USD 124m) in commitments.
PE-backed Adlai Nortye pursues US listing
Adlai Nortye, a private equity-backed Chinese cancer drug developer that previously filed to list in Hong Kong, is now targeting an IPO in the US.
Deal focus: TH Capital identifies key niche in energy storage
Zhongchu Guoneng Technology is leading China’s push into compressed air energy storage as a means of harnessing fast-rising yet unstable wind and solar capacity. Tsinghua Holdings Capital is among the backers
China energy storage start-up gets $48m pre-Series A
Zhongchu Guoneng Technology (ZGT), a China-based energy storage company, has raised CNY 320m (USD 48m) in pre-Series A funding led by Tsinghua Holdings Capital.
Hong Kong sees rush of VC-backed biotech IPO filings
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
China drug developer Adlai Nortye gets $100m Series D
Adlai Nortye, a Chinese biopharma player specializing in cancer treatments, has raised $100 million in Series D funding.
Legend Star raises $119m for fourth renminbi fund
Legend Star, the early-stage investment arm of China’s Legend Holdings, has raised RMB800 million ($119 million) for its fourth renminbi-denominated fund.